CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development [Yahoo! Finance]
CYTODYN INC (CYDY)
NASDAQ:AMEX Investor Relations:
ir.cytodyn.com
Company Research
Source: Yahoo! Finance
Dr. Lataillade brings over two decades of in-depth research experience to the CytoDyn team, with robust expertise investigating novel drug products and therapies. He most recently served as Vice President, Head of Early Development and Global Research Strategy at ViiV Healthcare, where he oversaw its novel HIV oral and long-acting pipeline. Prior to that, he was Vice President and Head of Global Development for HIV at Bristol-Myers Squibb, having joined the global clinical research group in 2007 as an infectious disease and HIV specialist. Dr. Lataillade is also currently an assistant clinical professor and teaching attending at the Yale University School of Medicine. “I am deeply enthusiastic to welcome Dr. Lataillade to the CytoDyn team. I have had several opportunities to collaborate with him over the past ten years and I believe his accomplishments in the industry and his skillset will help us progress our development pipeline,” said Dr. Jacob Lalezari, CEO. “I look forward to
Show less
Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYDY alerts
High impacting CYTODYN INC news events
Weekly update
A roundup of the hottest topics
CYDY
News
- CytoDyn Phase 2 study of leronlimab cleared by FDA [Seeking Alpha]Seeking Alpha
- CytoDyn Announces FDA Clearance of Its Phase II Oncology TrialGlobeNewswire
- CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC LaboratoriesGlobeNewswire
- CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical DevelopmentGlobeNewswire
- CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques [Yahoo! Finance]Yahoo! Finance
CYDY
Sec Filings
- 11/22/24 - Form 8-K
- 10/30/24 - Form 4
- 10/30/24 - Form 4
- CYDY's page on the SEC website